Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017–2018

Sayfutdinov Z, Kumar A, Nabirova D, Gadoev J, Turaev L, Sultanov S, Alaverdyan S, Parpieva N (2021)
International Journal of Environmental Research and Public Health 18(6): 2965.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
OA 284.16 KB
Autor*in
Sayfutdinov, Zayniddin; Kumar, Ajay; Nabirova, Dilyara; Gadoev, Jamshid; Turaev, Laziz; Sultanov, Sanjar; Alaverdyan, Sevak; Parpieva, Nargiza
Abstract / Bemerkung
Tuberculosis patients “resistant to isoniazid and susceptible to rifampicin (Hr-TB)” remain neglected, despite a high burden and poor outcomes. The World Health Organization (WHO) recommends a 6 month regimen consisting of levofloxacin, rifampicin, ethambutol, and pyrazinamide (LRZE) to treat Hr-TB. In contrast, Uzbekistan uses a 9 month regimen (LRZE plus a second-line injectable in the first 3 months). We aimed to assess the treatment outcomes of this novel regimen among Hr-TB patients treated in two regions of Uzbekistan (Fergana and Bukhara) in 2017–2018. We conducted a cohort study involving secondary analysis of routine surveillance data. Of 132 Hr-TB patients, 105 (80%) were successfully treated. Death was the predominant unsuccessful outcome (13, 10%) followed by “treatment failure” (10, 8%) and “lost to follow-up” (4, 2%). High treatment success is an indicator of the potential effectiveness of the novel regimen and adds to the limited global evidence on this issue. However, the sample size was small and there was no comparison group. Since the study was conducted in two regions of Uzbekistan only, the findings have limited generalizability. We recommend future research using an adequate sample size and an appropriate study design (randomized controlled trial or prospective cohort with a control group receiving the WHO-recommended regimen).
Erscheinungsjahr
2021
Zeitschriftentitel
International Journal of Environmental Research and Public Health
Band
18
Ausgabe
6
Art.-Nr.
2965
eISSN
1660-4601
Page URI
https://pub.uni-bielefeld.de/record/2954847

Zitieren

Sayfutdinov Z, Kumar A, Nabirova D, et al. Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017–2018. International Journal of Environmental Research and Public Health. 2021;18(6): 2965.
Sayfutdinov, Z., Kumar, A., Nabirova, D., Gadoev, J., Turaev, L., Sultanov, S., Alaverdyan, S., et al. (2021). Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017–2018. International Journal of Environmental Research and Public Health, 18(6), 2965. https://doi.org/10.3390/ijerph18062965
Sayfutdinov, Z., Kumar, A., Nabirova, D., Gadoev, J., Turaev, L., Sultanov, S., Alaverdyan, S., and Parpieva, N. (2021). Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017–2018. International Journal of Environmental Research and Public Health 18:2965.
Sayfutdinov, Z., et al., 2021. Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017–2018. International Journal of Environmental Research and Public Health, 18(6): 2965.
Z. Sayfutdinov, et al., “Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017–2018”, International Journal of Environmental Research and Public Health, vol. 18, 2021, : 2965.
Sayfutdinov, Z., Kumar, A., Nabirova, D., Gadoev, J., Turaev, L., Sultanov, S., Alaverdyan, S., Parpieva, N.: Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017–2018. International Journal of Environmental Research and Public Health. 18, : 2965 (2021).
Sayfutdinov, Zayniddin, Kumar, Ajay, Nabirova, Dilyara, Gadoev, Jamshid, Turaev, Laziz, Sultanov, Sanjar, Alaverdyan, Sevak, and Parpieva, Nargiza. “Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017–2018”. International Journal of Environmental Research and Public Health 18.6 (2021): 2965.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Creative Commons Namensnennung 4.0 International Public License (CC-BY 4.0):
Volltext(e)
Access Level
OA Open Access
Zuletzt Hochgeladen
2021-05-17T09:45:59Z
MD5 Prüfsumme
5b5fb7b5730a0d33f0c794be45a3d633

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 33799350
PubMed | Europe PMC

Suchen in

Google Scholar